Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics is attractive because ZEVASKYN is an approved, high-value autologous gene therapy with demonstrated durability, safety, and meaningful wound-healing benefits in RDEB, a ~750-patient U.S. pool with few strong options. Commercial momentum is building, with 1Q26 revenue of $8.7M, six active QTC sites, 95% coverage of commercially insured U.S. lives, and forecast revenue of $52.1M in 2026 and $97.4M in 2027, supporting a path to cash flow-positive status once annualized revenue stays below $100M. Further upside comes from a scalable Cleveland manufacturing footprint, manageable 25-day turnaround, and partnered programs that can generate up to 10% royalties and as much as $30M in milestone payments, while AAV ophthalmology assets add optionality.

Abeona Therapeutics is facing a negative fundamental setup because its gene-therapy business carries outsized clinical, regulatory, manufacturing, and reimbursement risks, including serious adverse events, heightened scrutiny, complex production requirements, and potential payor resistance to high-cost treatments. Operationally, the 2Q result showed execution weakness: revenue of $11.4M missed expectations of $13.4M/12.1M, only four of five treated patients were billable, and low manufacturing yield, biopsy-quality issues, cancellations, and a failed identity test highlighted fragile process reliability. With management and the model now assuming a 5-10% production failure rate moving forward, the company also faces lower-than-expected ZEVASKYN penetration and a greater-than-anticipated need for financing.